3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
3
Thrombocytopenia
2
Pathologic Complete Response
2
Uterine Cervical Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Leukemia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
38
Bevacizumab
25
Cyclophosphamide
22
Blood Specimen Collection
18
Nivolumab
17
Carboplatin
16
Standard of Care
14
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
12
Cisplatin
12
Fluorouracil
11
Doxorubicin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Dexamethasone
8
Biopsy
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Tretinoin
×
90 days
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled